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The perfect storm
The editor-in-chief of the Lancet, Richard Horton, re-
cently called the intersection of the COVID-19 pan-
demic with the epidemic of increasing chronic disease
burden an “acute-on-chronic health emergency”.[1]
The Institute for Health Metrics and Evaluation at the
University of Washington describes the rising world-
wide chronic disease burden and public health fail-
ures as “fueling” the COVID-19 pandemic.[1, 2] Prior
to the pandemic, polypharmacy per capita was steadily
increasing over decades due to many factors, but es-
pecially because of increased chronic disease burden
among the general population worldwide.[3, 4]
Chronic disease, and more post-COVID-19
chronic disease
We are learning that post-acute sequelae of COVID-
19 (PASC) in many ways parallel post-intensive care
syndrome (PICS), with persistent physical, cognitive
and psychological sequelae impacting quality of life.[5]
This implies that many recovered COVID-19 patients
will live with increased disease burden and accompa-
nying polypharmacy, in addition to their pre-COVID-
19 conditions and medications. The wide variety of
PASC reported within the first year of the pandemic
indicates that PASC patients will experience an abrupt
increase in per patient burden of diagnoses in the near
term and possibly permanently.[6]
In addition to PASC patients, there are an unknown
number of milder COVID-19 infection cases. Regard-
less of the severity of infection, it is clear that prolonged
after-effects of COVID-19 after treatment or hospital-
ization do exist.[7] Johansson et al. report that even out-
patient COVID-19 infection cases can have non-specific
symptoms of autonomic dysfunction, blood pressure
dysregulation, and orthostatic intolerance (postural or-
thostatic tachycardia syndrome, or POTS).[8] Multi-
ple neurological sequelae of COVID-19 infection have
also been reported, including cerebrovascular disor-
ders (stroke, vasculitis), altered mental status (en-
cephalitis, encephalopathy, seizures), peripheral ner-
vous system problems (myositis, Guillain-Barre syn-
drome), movement disorders (ataxia, myoclonus and
opsoclonus), and neuropsychiatric problems (depres-
sion, personality change, mania, psychosis, and cata-
tonia).[9]
In March 2021, results were published from an ongo-
ing prospective study in the United Kingdom with a
cohort of 201 community-based low-risk post-COVID-
19 patients (mean age 45; range 21–71). The patients
reported fatigue (98%), muscle aches (87%), breathless-
ness (88%), and headaches (83%). Mild organ impair-
ment was present in the heart (26%), lungs (11%), kid-
neys (4%), liver (28%), pancreas (40%), and spleen (4%),
with single organ (70%) and multiorgan (29%) impair-
ment. In this study, severe PASC was associated with
radiological evidence of cardiac damage.[10]
Yet another perfect storm
The intersection of the COVID-19 pandemic with the
epidemic of increasing chronic disease burden world-
wide has been called “the perfect storm”.[1] The ex-
pected burden of additional diagnosis in post-COVID-
19 patients, with high antecedent chronic disease bur-
dens and accompanying polypharmacy, is yet an-
other perfect storm, especially for the most vulnera-
ble COVID-19 patients: older persons.[11] Older adults
tend to have multiple comorbidities and have the high-
est level of polypharmacy use in society, even pre-
COVID-19.[12] The prevalence of polypharmacy in-
creases proportionally with increasing age.[12] Older
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persons are seven times more likely to be hospital-
ized for adverse drug events than younger persons.[13]
In the United States and Europe, the number of peo-
ple taking five or more prescription drugs (not count-
ing over-the-counter medications, herbal supplements,
and vitamins) is increasing rapidly. One study reported
that 85% of older adults with cancer received five or
more prescription medications, and 43% received ten or
more.[14] Cancer.org reports the risk of living with can-
cer in adults 85 years and older is 1 in 6 for men and 1 in
8 for women, and this age cohort is expected to triple by
2060.[15] Older adults typically live with chronic sub-
clinical systemic inflammation, a heightened baseline
inflammatory status termed “inflammaging.” Inflam-
maging is thought to start in middle age and clinically
presents as excessive chronic disease. Inflammaging
is associated (causally in many cases) with age-related
diseases, such as insulin resistance, cardiovascular dis-
ease, osteoarthritis, COPD, emphysema, pulmonary ar-
terial hypertension, Alzheimer’s disease, Parkinson’s
disease, macular degeneration, sarcopenia, immunose-
nescence, and frailty.[16]
Hyperinflammatory syndromes—such as SARS-CoV-
2 (COVID-19), ARDS, cytokine storm syndrome, and
PICS—are associated with short- and long-term seque-
lae following recovery. These syndromes lead to an ac-
celerated state of chronic subclinical inflammation and
an increase or worsening of age-related conditions, in-
cluding frailty in older (as well as potentially younger)
persons with PASC who are already living with high
chronic disease burden.[16] Medical scholars expect
post-COVID-19 patients to experience accelerated in-
flammaging.
It is not difficult to see how polypharmacy levels will
dramatically increase due to the COVID-19 pandemic,
given the anticipated burden of PASC conditions and
the potential for accelerated inflammaging. Clinicians
are already anxious about the impact of added neu-
rocognitive and psychiatric conditions that result from
heavy burdens of medical comorbidities. Layering
neuropsychiatric problems on top of chronic metabolic
and inflammatory disease presents a difficult and com-
plicated medication management challenge.[17] Addi-
tionally, medications can interfere with clinical tests
and outcomes.[18, 19]
Consider the case scenario of polypharmacy in an
older male patient with multiple chronic diseases, dis-
charged from hospital after acute COVID-19 infection,
who now has seizures and survived an acute myocar-
dial infarction due to the COVID-19 infection. The pa-
tient now lives with anxiety, insomnia, and depression
because of post–acute COVID-19 change in functional
status and an increased level of frailty (Figure 1).[20,
21]
This patient was discharged with a new prescriptions
for a beta blocker (metoprolol), because he had an acute
myocardial infarction, and levetiracetam for new-onset
seizures also caused by the acute COVID-19 infection.
The patient was also discharged with a tramadol pre-
scription for persistent pain. Two months after hospital
discharge, because the patient became depressed about
diminished post–acute COVID-19 functional status, he
was prescribed fluoxetine by his community physician.
The levetiracetam was dosed too high for the patient’s
renal function, resulting in restlessness and psychiatric
adverse effects. The patient’s family took the patient to
the grocery store easy-access clinic for symptoms of in-
somnia, where he was prescribed trazodone. An acute
COVID-19 episode can cause post-COVID-19 seque-
lae that significantly increase a patient’s polypharmacy
burden. Increased polypharmacy burden increases the
risk of adverse events, and for this patient, there are
several new medication burden–related threats. The
tramadol may not be effective because fluoxetine in-
hibits conversion to active drug; fluoxetine also inhibits
metabolism of active metoprolol, which may put the
patient at risk of bradycardia and hypotension. The flu-
oxetine may interact with the patient’s existing simvas-
tatin prescription and cause muscle pain or rhabdomy-
olysis. Furthermore, levetiracetam toxicity may be un-
recognized and misdiagnosed as new-onset psychosis
or dementia and start a prescribing cascade to address
medication-induced symptoms.
Significance of expected post COVID-19
syndrome hyper-polypharmacy
The potential for hyper-polypharmacy worldwide due
to the COVID-19 pandemic is significant. At a time
when societies are trying to gain control over ram-
pant polypharmacy with large government-sponsored
programs, such as “Polypharmacy Management by
2030” in the European Union, the “Canadian Depre-
scribing Network,” the “US Deprescribing Research
Network,” and Australia’s “National Prescribing Ser-
vice Medicinewise,” it is daunting to think about
the potential for added medication load per capita
around the world due to PASC and post–outpatient
COVID-19 syndrome.[12, 22-24] Well-intentioned med-
ication use in 2016 was responsible for 275,689 deaths
and cost $528.4 billion dollars.[25] This means that if
medication-related problems were a disease counted
by the Centers for Disease Control as a cause of death
in the United States, it would rank as the third lead-
ing cause of death behind cancer and heart disease, but
ahead of diabetes, Alzheimer’s disease and others.[26]
Most medication-related problems are avoidable with
the optimization of adherence, prescribing practices,
and, most importantly, monitoring.[27, 28] The more
complex the patient and the higher the number of
medications, supplements and vitamins used concomi-
tantly, the more challenging medication use optimiza-
tion becomes. Therefore, the COVID-19 pandemic may
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Figure 1. Scenario of an older adult with multiple chronic conditions, pre- and post-PASC. In addition to several new comorbidities, including
added neurologic and psychiatric diagnoses, his added polypharmacy introduces an entire cascade of new problems.
∗Self-prescribed.
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in time raise the death toll and costs of non-optimized
medication use well beyond the third leading cause of
death and $528 billion. Additionally, the added layers
of complex psychoactive and chronic disease manage-
ment medications will make adverse drug-drug and
drug-disease interactions, as well as toxidromes, more
common, posing a difficult clinical management sce-
nario for clinicians.
Conclusion
PASC patients are beginning to be characterized by
biomedical scholars. It would be of value to char-
acterize, quantify, and study approaches to the ex-
pected increase in rates of polypharmacy and poten-
tial cascade of new medication-related problems. From
a public health and biomedical science perspective,
polypharmacy has been as difficult a problem to tackle
as the growing burden of chronic disease. Unman-
aged polypharmacy is very costly in terms of morbid-
ity and mortality, as well as monetarily. Tracking the
count of pre-COVID-19 infection and post-COVID-19-
episode medication burden, as well as characterization
of medications used to treat post-COVID-19 symptoms,
will help public health professionals, biomedical scien-
tists, and stake holders address avoidable harm caused
by complex medication use.
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